nodes	percent_of_prediction	percent_of_DWPC	metapath
Labetalol—Dobutamine—CA2—osteoporosis	0.00589	0.333	CrCbGaD
Labetalol—Benazepril—MTHFR—osteoporosis	0.00429	0.242	CrCbGaD
Labetalol—Quinapril—ACE—osteoporosis	0.00402	0.227	CrCbGaD
Labetalol—Benazepril—ACE—osteoporosis	0.0035	0.198	CrCbGaD
Labetalol—Body temperature increased—Estropipate—osteoporosis	0.00142	0.00149	CcSEcCtD
Labetalol—Feeling abnormal—Ibandronate—osteoporosis	0.00142	0.00149	CcSEcCtD
Labetalol—Tremor—Zoledronate—osteoporosis	0.00142	0.00149	CcSEcCtD
Labetalol—Gastrointestinal pain—Ibandronate—osteoporosis	0.00141	0.00148	CcSEcCtD
Labetalol—Urticaria—Alendronate—osteoporosis	0.00141	0.00148	CcSEcCtD
Labetalol—Epistaxis—Estradiol—osteoporosis	0.00141	0.00148	CcSEcCtD
Labetalol—Ill-defined disorder—Zoledronate—osteoporosis	0.00141	0.00147	CcSEcCtD
Labetalol—Abdominal pain—Alendronate—osteoporosis	0.0014	0.00147	CcSEcCtD
Labetalol—Body temperature increased—Alendronate—osteoporosis	0.0014	0.00147	CcSEcCtD
Labetalol—Muscle spasms—Conjugated Estrogens—osteoporosis	0.0014	0.00147	CcSEcCtD
Labetalol—Shock—Risedronate—osteoporosis	0.0014	0.00147	CcSEcCtD
Labetalol—Discomfort—Pamidronate—osteoporosis	0.0014	0.00146	CcSEcCtD
Labetalol—Angioedema—Zoledronate—osteoporosis	0.00138	0.00145	CcSEcCtD
Labetalol—Gastrointestinal pain—Calcitriol—osteoporosis	0.00138	0.00145	CcSEcCtD
Labetalol—Abdominal pain—Raloxifene—osteoporosis	0.00138	0.00144	CcSEcCtD
Labetalol—Body temperature increased—Raloxifene—osteoporosis	0.00138	0.00144	CcSEcCtD
Labetalol—Vision blurred—Conjugated Estrogens—osteoporosis	0.00138	0.00144	CcSEcCtD
Labetalol—Urticaria—Ibandronate—osteoporosis	0.00137	0.00144	CcSEcCtD
Labetalol—Malaise—Zoledronate—osteoporosis	0.00137	0.00143	CcSEcCtD
Labetalol—Abdominal pain—Ibandronate—osteoporosis	0.00137	0.00143	CcSEcCtD
Labetalol—Body temperature increased—Ibandronate—osteoporosis	0.00137	0.00143	CcSEcCtD
Labetalol—Confusional state—Pamidronate—osteoporosis	0.00137	0.00143	CcSEcCtD
Labetalol—Vertigo—Zoledronate—osteoporosis	0.00136	0.00143	CcSEcCtD
Labetalol—Syncope—Zoledronate—osteoporosis	0.00136	0.00142	CcSEcCtD
Labetalol—Anaphylactic shock—Pamidronate—osteoporosis	0.00135	0.00142	CcSEcCtD
Labetalol—Oedema—Pamidronate—osteoporosis	0.00135	0.00142	CcSEcCtD
Labetalol—Urticaria—Calcitriol—osteoporosis	0.00134	0.00141	CcSEcCtD
Labetalol—Hepatitis—Estradiol—osteoporosis	0.00134	0.0014	CcSEcCtD
Labetalol—Palpitations—Zoledronate—osteoporosis	0.00134	0.0014	CcSEcCtD
Labetalol—Abdominal pain—Calcitriol—osteoporosis	0.00134	0.0014	CcSEcCtD
Labetalol—Body temperature increased—Calcitriol—osteoporosis	0.00134	0.0014	CcSEcCtD
Labetalol—Hypoaesthesia—Estradiol—osteoporosis	0.00133	0.0014	CcSEcCtD
Labetalol—Angioedema—Conjugated Estrogens—osteoporosis	0.00133	0.0014	CcSEcCtD
Labetalol—Shock—Pamidronate—osteoporosis	0.00133	0.00139	CcSEcCtD
Labetalol—Loss of consciousness—Zoledronate—osteoporosis	0.00133	0.00139	CcSEcCtD
Labetalol—Hypersensitivity—Estropipate—osteoporosis	0.00133	0.00139	CcSEcCtD
Labetalol—Vomiting—Etidronic acid—osteoporosis	0.00132	0.00139	CcSEcCtD
Labetalol—Oedema peripheral—Estradiol—osteoporosis	0.00132	0.00138	CcSEcCtD
Labetalol—Rash—Etidronic acid—osteoporosis	0.00131	0.00137	CcSEcCtD
Labetalol—Dermatitis—Etidronic acid—osteoporosis	0.00131	0.00137	CcSEcCtD
Labetalol—Vertigo—Conjugated Estrogens—osteoporosis	0.00131	0.00137	CcSEcCtD
Labetalol—Hyperhidrosis—Pamidronate—osteoporosis	0.00131	0.00137	CcSEcCtD
Labetalol—Syncope—Conjugated Estrogens—osteoporosis	0.00131	0.00137	CcSEcCtD
Labetalol—Hypertension—Zoledronate—osteoporosis	0.00131	0.00137	CcSEcCtD
Labetalol—Hypersensitivity—Alendronate—osteoporosis	0.00131	0.00137	CcSEcCtD
Labetalol—Headache—Etidronic acid—osteoporosis	0.00131	0.00137	CcSEcCtD
Labetalol—Asthenia—Estropipate—osteoporosis	0.00129	0.00135	CcSEcCtD
Labetalol—Visual impairment—Estradiol—osteoporosis	0.00129	0.00135	CcSEcCtD
Labetalol—Palpitations—Conjugated Estrogens—osteoporosis	0.00129	0.00135	CcSEcCtD
Labetalol—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.00128	0.00134	CcSEcCtD
Labetalol—Paraesthesia—Risedronate—osteoporosis	0.00128	0.00134	CcSEcCtD
Labetalol—Pruritus—Estropipate—osteoporosis	0.00128	0.00133	CcSEcCtD
Labetalol—Discomfort—Zoledronate—osteoporosis	0.00127	0.00133	CcSEcCtD
Labetalol—Asthenia—Alendronate—osteoporosis	0.00127	0.00133	CcSEcCtD
Labetalol—Hypersensitivity—Ibandronate—osteoporosis	0.00127	0.00133	CcSEcCtD
Labetalol—Dyspnoea—Risedronate—osteoporosis	0.00127	0.00133	CcSEcCtD
Labetalol—Hypotension—Pamidronate—osteoporosis	0.00127	0.00132	CcSEcCtD
Labetalol—Fatigue—Ethinyl Estradiol—osteoporosis	0.00126	0.00132	CcSEcCtD
Labetalol—Pruritus—Alendronate—osteoporosis	0.00126	0.00131	CcSEcCtD
Labetalol—Dyspepsia—Risedronate—osteoporosis	0.00125	0.00131	CcSEcCtD
Labetalol—Constipation—Ethinyl Estradiol—osteoporosis	0.00125	0.00131	CcSEcCtD
Labetalol—Confusional state—Zoledronate—osteoporosis	0.00125	0.00131	CcSEcCtD
Labetalol—Hypersensitivity—Calcitriol—osteoporosis	0.00125	0.0013	CcSEcCtD
Labetalol—Flushing—Estradiol—osteoporosis	0.00125	0.0013	CcSEcCtD
Labetalol—Asthenia—Ibandronate—osteoporosis	0.00124	0.0013	CcSEcCtD
Labetalol—Nausea—Etidronic acid—osteoporosis	0.00124	0.0013	CcSEcCtD
Labetalol—Anaphylactic shock—Zoledronate—osteoporosis	0.00124	0.00129	CcSEcCtD
Labetalol—Oedema—Zoledronate—osteoporosis	0.00124	0.00129	CcSEcCtD
Labetalol—Diarrhoea—Estropipate—osteoporosis	0.00123	0.00129	CcSEcCtD
Labetalol—Fatigue—Risedronate—osteoporosis	0.00123	0.00129	CcSEcCtD
Labetalol—Pruritus—Ibandronate—osteoporosis	0.00122	0.00128	CcSEcCtD
Labetalol—Constipation—Risedronate—osteoporosis	0.00122	0.00127	CcSEcCtD
Labetalol—Pain—Risedronate—osteoporosis	0.00122	0.00127	CcSEcCtD
Labetalol—Shock—Zoledronate—osteoporosis	0.00122	0.00127	CcSEcCtD
Labetalol—Paraesthesia—Pamidronate—osteoporosis	0.00122	0.00127	CcSEcCtD
Labetalol—Diarrhoea—Alendronate—osteoporosis	0.00121	0.00127	CcSEcCtD
Labetalol—Asthenia—Calcitriol—osteoporosis	0.00121	0.00127	CcSEcCtD
Labetalol—Dyspnoea—Pamidronate—osteoporosis	0.00121	0.00126	CcSEcCtD
Labetalol—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.0012	0.00126	CcSEcCtD
Labetalol—Somnolence—Pamidronate—osteoporosis	0.0012	0.00126	CcSEcCtD
Labetalol—Pruritus—Calcitriol—osteoporosis	0.0012	0.00125	CcSEcCtD
Labetalol—Hyperhidrosis—Zoledronate—osteoporosis	0.0012	0.00125	CcSEcCtD
Labetalol—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.00119	0.00125	CcSEcCtD
Labetalol—Diarrhoea—Raloxifene—osteoporosis	0.00119	0.00125	CcSEcCtD
Labetalol—Dyspepsia—Pamidronate—osteoporosis	0.00119	0.00125	CcSEcCtD
Labetalol—Dizziness—Estropipate—osteoporosis	0.00119	0.00125	CcSEcCtD
Labetalol—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.00119	0.00125	CcSEcCtD
Labetalol—Oedema—Conjugated Estrogens—osteoporosis	0.00119	0.00125	CcSEcCtD
Labetalol—Alopecia—Estradiol—osteoporosis	0.00119	0.00124	CcSEcCtD
Labetalol—Diarrhoea—Ibandronate—osteoporosis	0.00118	0.00124	CcSEcCtD
Labetalol—Mental disorder—Estradiol—osteoporosis	0.00118	0.00123	CcSEcCtD
Labetalol—Dizziness—Alendronate—osteoporosis	0.00117	0.00123	CcSEcCtD
Labetalol—Shock—Conjugated Estrogens—osteoporosis	0.00117	0.00123	CcSEcCtD
Labetalol—Erythema—Estradiol—osteoporosis	0.00117	0.00122	CcSEcCtD
Labetalol—Fatigue—Pamidronate—osteoporosis	0.00117	0.00122	CcSEcCtD
Labetalol—Gastrointestinal pain—Risedronate—osteoporosis	0.00116	0.00122	CcSEcCtD
Labetalol—Urticaria—Ethinyl Estradiol—osteoporosis	0.00116	0.00121	CcSEcCtD
Labetalol—Pain—Pamidronate—osteoporosis	0.00116	0.00121	CcSEcCtD
Labetalol—Constipation—Pamidronate—osteoporosis	0.00116	0.00121	CcSEcCtD
Labetalol—Diarrhoea—Calcitriol—osteoporosis	0.00116	0.00121	CcSEcCtD
Labetalol—Hypotension—Zoledronate—osteoporosis	0.00116	0.00121	CcSEcCtD
Labetalol—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.00115	0.00121	CcSEcCtD
Labetalol—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.00115	0.00121	CcSEcCtD
Labetalol—Dizziness—Raloxifene—osteoporosis	0.00115	0.00121	CcSEcCtD
Labetalol—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.00115	0.00121	CcSEcCtD
Labetalol—Vomiting—Estropipate—osteoporosis	0.00115	0.0012	CcSEcCtD
Labetalol—Dizziness—Ibandronate—osteoporosis	0.00114	0.0012	CcSEcCtD
Labetalol—Rash—Estropipate—osteoporosis	0.00114	0.00119	CcSEcCtD
Labetalol—Dermatitis—Estropipate—osteoporosis	0.00114	0.00119	CcSEcCtD
Labetalol—Urticaria—Risedronate—osteoporosis	0.00113	0.00118	CcSEcCtD
Labetalol—Headache—Estropipate—osteoporosis	0.00113	0.00118	CcSEcCtD
Labetalol—Vomiting—Alendronate—osteoporosis	0.00113	0.00118	CcSEcCtD
Labetalol—Body temperature increased—Risedronate—osteoporosis	0.00113	0.00118	CcSEcCtD
Labetalol—Abdominal pain—Risedronate—osteoporosis	0.00113	0.00118	CcSEcCtD
Labetalol—Muscle spasms—Estradiol—osteoporosis	0.00112	0.00118	CcSEcCtD
Labetalol—Rash—Alendronate—osteoporosis	0.00112	0.00117	CcSEcCtD
Labetalol—Dermatitis—Alendronate—osteoporosis	0.00112	0.00117	CcSEcCtD
Labetalol—Feeling abnormal—Pamidronate—osteoporosis	0.00112	0.00117	CcSEcCtD
Labetalol—Hypotension—Conjugated Estrogens—osteoporosis	0.00111	0.00116	CcSEcCtD
Labetalol—Headache—Alendronate—osteoporosis	0.00111	0.00116	CcSEcCtD
Labetalol—Paraesthesia—Zoledronate—osteoporosis	0.00111	0.00116	CcSEcCtD
Labetalol—Vomiting—Raloxifene—osteoporosis	0.00111	0.00116	CcSEcCtD
Labetalol—Gastrointestinal pain—Pamidronate—osteoporosis	0.00111	0.00116	CcSEcCtD
Labetalol—Dyspnoea—Zoledronate—osteoporosis	0.0011	0.00115	CcSEcCtD
Labetalol—Rash—Raloxifene—osteoporosis	0.0011	0.00115	CcSEcCtD
Labetalol—Dermatitis—Raloxifene—osteoporosis	0.0011	0.00115	CcSEcCtD
Labetalol—Somnolence—Zoledronate—osteoporosis	0.0011	0.00115	CcSEcCtD
Labetalol—Vomiting—Ibandronate—osteoporosis	0.0011	0.00115	CcSEcCtD
Labetalol—Tremor—Estradiol—osteoporosis	0.00109	0.00115	CcSEcCtD
Labetalol—Headache—Raloxifene—osteoporosis	0.00109	0.00114	CcSEcCtD
Labetalol—Rash—Ibandronate—osteoporosis	0.00109	0.00114	CcSEcCtD
Labetalol—Dermatitis—Ibandronate—osteoporosis	0.00109	0.00114	CcSEcCtD
Labetalol—Dyspepsia—Zoledronate—osteoporosis	0.00109	0.00114	CcSEcCtD
Labetalol—Ill-defined disorder—Estradiol—osteoporosis	0.00108	0.00113	CcSEcCtD
Labetalol—Headache—Ibandronate—osteoporosis	0.00108	0.00113	CcSEcCtD
Labetalol—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.00108	0.00113	CcSEcCtD
Labetalol—Vomiting—Calcitriol—osteoporosis	0.00108	0.00113	CcSEcCtD
Labetalol—Nausea—Estropipate—osteoporosis	0.00107	0.00112	CcSEcCtD
Labetalol—Abdominal pain—Pamidronate—osteoporosis	0.00107	0.00112	CcSEcCtD
Labetalol—Body temperature increased—Pamidronate—osteoporosis	0.00107	0.00112	CcSEcCtD
Labetalol—Paraesthesia—Conjugated Estrogens—osteoporosis	0.00107	0.00112	CcSEcCtD
Labetalol—Angioedema—Estradiol—osteoporosis	0.00107	0.00112	CcSEcCtD
Labetalol—Rash—Calcitriol—osteoporosis	0.00107	0.00112	CcSEcCtD
Labetalol—Fatigue—Zoledronate—osteoporosis	0.00107	0.00112	CcSEcCtD
Labetalol—Dermatitis—Calcitriol—osteoporosis	0.00107	0.00112	CcSEcCtD
Labetalol—Dyspnoea—Conjugated Estrogens—osteoporosis	0.00106	0.00111	CcSEcCtD
Labetalol—Headache—Calcitriol—osteoporosis	0.00106	0.00111	CcSEcCtD
Labetalol—Somnolence—Conjugated Estrogens—osteoporosis	0.00106	0.00111	CcSEcCtD
Labetalol—Pain—Zoledronate—osteoporosis	0.00106	0.00111	CcSEcCtD
Labetalol—Constipation—Zoledronate—osteoporosis	0.00106	0.00111	CcSEcCtD
Labetalol—Nausea—Alendronate—osteoporosis	0.00105	0.0011	CcSEcCtD
Labetalol—Malaise—Estradiol—osteoporosis	0.00105	0.0011	CcSEcCtD
Labetalol—Hypersensitivity—Risedronate—osteoporosis	0.00105	0.0011	CcSEcCtD
Labetalol—Vertigo—Estradiol—osteoporosis	0.00105	0.0011	CcSEcCtD
Labetalol—Dyspepsia—Conjugated Estrogens—osteoporosis	0.00105	0.0011	CcSEcCtD
Labetalol—Asthenia—Ethinyl Estradiol—osteoporosis	0.00105	0.0011	CcSEcCtD
Labetalol—Syncope—Estradiol—osteoporosis	0.00105	0.0011	CcSEcCtD
Labetalol—Nausea—Raloxifene—osteoporosis	0.00104	0.00109	CcSEcCtD
Labetalol—Pruritus—Ethinyl Estradiol—osteoporosis	0.00103	0.00108	CcSEcCtD
Labetalol—Palpitations—Estradiol—osteoporosis	0.00103	0.00108	CcSEcCtD
Labetalol—Fatigue—Conjugated Estrogens—osteoporosis	0.00103	0.00107	CcSEcCtD
Labetalol—Nausea—Ibandronate—osteoporosis	0.00103	0.00107	CcSEcCtD
Labetalol—Loss of consciousness—Estradiol—osteoporosis	0.00103	0.00107	CcSEcCtD
Labetalol—Asthenia—Risedronate—osteoporosis	0.00102	0.00107	CcSEcCtD
Labetalol—Feeling abnormal—Zoledronate—osteoporosis	0.00102	0.00107	CcSEcCtD
Labetalol—Constipation—Conjugated Estrogens—osteoporosis	0.00102	0.00107	CcSEcCtD
Labetalol—Pain—Conjugated Estrogens—osteoporosis	0.00102	0.00107	CcSEcCtD
Labetalol—Gastrointestinal pain—Zoledronate—osteoporosis	0.00101	0.00106	CcSEcCtD
Labetalol—Hypertension—Estradiol—osteoporosis	0.00101	0.00106	CcSEcCtD
Labetalol—Pruritus—Risedronate—osteoporosis	0.00101	0.00105	CcSEcCtD
Labetalol—Nausea—Calcitriol—osteoporosis	0.001	0.00105	CcSEcCtD
Labetalol—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.001	0.00105	CcSEcCtD
Labetalol—Hypersensitivity—Pamidronate—osteoporosis	0.000998	0.00104	CcSEcCtD
Labetalol—Urticaria—Zoledronate—osteoporosis	0.000983	0.00103	CcSEcCtD
Labetalol—Discomfort—Estradiol—osteoporosis	0.000982	0.00103	CcSEcCtD
Labetalol—Body temperature increased—Zoledronate—osteoporosis	0.000978	0.00102	CcSEcCtD
Labetalol—Abdominal pain—Zoledronate—osteoporosis	0.000978	0.00102	CcSEcCtD
Labetalol—Diarrhoea—Risedronate—osteoporosis	0.000975	0.00102	CcSEcCtD
Labetalol—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000974	0.00102	CcSEcCtD
Labetalol—Asthenia—Pamidronate—osteoporosis	0.000971	0.00102	CcSEcCtD
Labetalol—Dizziness—Ethinyl Estradiol—osteoporosis	0.000966	0.00101	CcSEcCtD
Labetalol—Confusional state—Estradiol—osteoporosis	0.000961	0.00101	CcSEcCtD
Labetalol—Pruritus—Pamidronate—osteoporosis	0.000958	0.001	CcSEcCtD
Labetalol—Oedema—Estradiol—osteoporosis	0.000953	0.000998	CcSEcCtD
Labetalol—Anaphylactic shock—Estradiol—osteoporosis	0.000953	0.000998	CcSEcCtD
Labetalol—Urticaria—Conjugated Estrogens—osteoporosis	0.000946	0.00099	CcSEcCtD
Labetalol—Dizziness—Risedronate—osteoporosis	0.000942	0.000986	CcSEcCtD
Labetalol—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000941	0.000985	CcSEcCtD
Labetalol—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000941	0.000985	CcSEcCtD
Labetalol—Shock—Estradiol—osteoporosis	0.000938	0.000982	CcSEcCtD
Labetalol—Vomiting—Ethinyl Estradiol—osteoporosis	0.000929	0.000972	CcSEcCtD
Labetalol—Diarrhoea—Pamidronate—osteoporosis	0.000926	0.00097	CcSEcCtD
Labetalol—Hyperhidrosis—Estradiol—osteoporosis	0.000921	0.000964	CcSEcCtD
Labetalol—Rash—Ethinyl Estradiol—osteoporosis	0.000921	0.000964	CcSEcCtD
Labetalol—Dermatitis—Ethinyl Estradiol—osteoporosis	0.00092	0.000963	CcSEcCtD
Labetalol—Headache—Ethinyl Estradiol—osteoporosis	0.000915	0.000958	CcSEcCtD
Labetalol—Hypersensitivity—Zoledronate—osteoporosis	0.000911	0.000954	CcSEcCtD
Labetalol—Vomiting—Risedronate—osteoporosis	0.000906	0.000948	CcSEcCtD
Labetalol—Rash—Risedronate—osteoporosis	0.000898	0.00094	CcSEcCtD
Labetalol—Dermatitis—Risedronate—osteoporosis	0.000897	0.000939	CcSEcCtD
Labetalol—Dizziness—Pamidronate—osteoporosis	0.000895	0.000937	CcSEcCtD
Labetalol—Headache—Risedronate—osteoporosis	0.000892	0.000934	CcSEcCtD
Labetalol—Asthenia—Zoledronate—osteoporosis	0.000887	0.000929	CcSEcCtD
Labetalol—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000877	0.000918	CcSEcCtD
Labetalol—Pruritus—Zoledronate—osteoporosis	0.000875	0.000916	CcSEcCtD
Labetalol—Nausea—Ethinyl Estradiol—osteoporosis	0.000868	0.000908	CcSEcCtD
Labetalol—Vomiting—Pamidronate—osteoporosis	0.000861	0.000901	CcSEcCtD
Labetalol—Paraesthesia—Estradiol—osteoporosis	0.000856	0.000896	CcSEcCtD
Labetalol—Asthenia—Conjugated Estrogens—osteoporosis	0.000854	0.000894	CcSEcCtD
Labetalol—Rash—Pamidronate—osteoporosis	0.000854	0.000894	CcSEcCtD
Labetalol—Dermatitis—Pamidronate—osteoporosis	0.000853	0.000893	CcSEcCtD
Labetalol—Dyspnoea—Estradiol—osteoporosis	0.00085	0.000889	CcSEcCtD
Labetalol—Headache—Pamidronate—osteoporosis	0.000848	0.000888	CcSEcCtD
Labetalol—Somnolence—Estradiol—osteoporosis	0.000847	0.000887	CcSEcCtD
Labetalol—Diarrhoea—Zoledronate—osteoporosis	0.000846	0.000886	CcSEcCtD
Labetalol—Nausea—Risedronate—osteoporosis	0.000846	0.000886	CcSEcCtD
Labetalol—Pruritus—Conjugated Estrogens—osteoporosis	0.000843	0.000882	CcSEcCtD
Labetalol—Dyspepsia—Estradiol—osteoporosis	0.000839	0.000878	CcSEcCtD
Labetalol—Fatigue—Estradiol—osteoporosis	0.000822	0.00086	CcSEcCtD
Labetalol—Dizziness—Zoledronate—osteoporosis	0.000818	0.000856	CcSEcCtD
Labetalol—Pain—Estradiol—osteoporosis	0.000815	0.000853	CcSEcCtD
Labetalol—Constipation—Estradiol—osteoporosis	0.000815	0.000853	CcSEcCtD
Labetalol—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000815	0.000853	CcSEcCtD
Labetalol—Nausea—Pamidronate—osteoporosis	0.000804	0.000842	CcSEcCtD
Labetalol—Dizziness—Conjugated Estrogens—osteoporosis	0.000788	0.000824	CcSEcCtD
Labetalol—Vomiting—Zoledronate—osteoporosis	0.000786	0.000823	CcSEcCtD
Labetalol—Feeling abnormal—Estradiol—osteoporosis	0.000785	0.000822	CcSEcCtD
Labetalol—Rash—Zoledronate—osteoporosis	0.00078	0.000816	CcSEcCtD
Labetalol—Gastrointestinal pain—Estradiol—osteoporosis	0.000779	0.000816	CcSEcCtD
Labetalol—Dermatitis—Zoledronate—osteoporosis	0.000779	0.000815	CcSEcCtD
Labetalol—Headache—Zoledronate—osteoporosis	0.000775	0.000811	CcSEcCtD
Labetalol—Vomiting—Conjugated Estrogens—osteoporosis	0.000757	0.000793	CcSEcCtD
Labetalol—Urticaria—Estradiol—osteoporosis	0.000757	0.000793	CcSEcCtD
Labetalol—Abdominal pain—Estradiol—osteoporosis	0.000753	0.000789	CcSEcCtD
Labetalol—Body temperature increased—Estradiol—osteoporosis	0.000753	0.000789	CcSEcCtD
Labetalol—Rash—Conjugated Estrogens—osteoporosis	0.000751	0.000786	CcSEcCtD
Labetalol—Dermatitis—Conjugated Estrogens—osteoporosis	0.00075	0.000785	CcSEcCtD
Labetalol—Headache—Conjugated Estrogens—osteoporosis	0.000746	0.000781	CcSEcCtD
Labetalol—Nausea—Zoledronate—osteoporosis	0.000735	0.000769	CcSEcCtD
Labetalol—Nausea—Conjugated Estrogens—osteoporosis	0.000707	0.00074	CcSEcCtD
Labetalol—Hypersensitivity—Estradiol—osteoporosis	0.000702	0.000735	CcSEcCtD
Labetalol—Asthenia—Estradiol—osteoporosis	0.000684	0.000716	CcSEcCtD
Labetalol—Pruritus—Estradiol—osteoporosis	0.000674	0.000706	CcSEcCtD
Labetalol—Diarrhoea—Estradiol—osteoporosis	0.000652	0.000683	CcSEcCtD
Labetalol—Dizziness—Estradiol—osteoporosis	0.00063	0.00066	CcSEcCtD
Labetalol—Vomiting—Estradiol—osteoporosis	0.000606	0.000634	CcSEcCtD
Labetalol—Rash—Estradiol—osteoporosis	0.000601	0.000629	CcSEcCtD
Labetalol—Dermatitis—Estradiol—osteoporosis	0.0006	0.000628	CcSEcCtD
Labetalol—Headache—Estradiol—osteoporosis	0.000597	0.000625	CcSEcCtD
Labetalol—Nausea—Estradiol—osteoporosis	0.000566	0.000593	CcSEcCtD
Labetalol—ADRB3—GPCR ligand binding—PTH1R—osteoporosis	0.000385	0.0143	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—CALCR—osteoporosis	0.000385	0.0143	CbGpPWpGaD
Labetalol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.00035	0.013	CbGpPWpGaD
Labetalol—CYP2D6—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000345	0.0128	CbGpPWpGaD
Labetalol—ADRB1—G alpha (s) signalling events—PTH—osteoporosis	0.00033	0.0123	CbGpPWpGaD
Labetalol—ADRB2—G alpha (s) signalling events—PTH—osteoporosis	0.000323	0.012	CbGpPWpGaD
Labetalol—ADRB3—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.000302	0.0112	CbGpPWpGaD
Labetalol—ADRB3—G alpha (s) signalling events—ADCY5—osteoporosis	0.000289	0.0107	CbGpPWpGaD
Labetalol—CYP2D6—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000284	0.0105	CbGpPWpGaD
Labetalol—ADRB1—G alpha (s) signalling events—PTHLH—osteoporosis	0.000274	0.0102	CbGpPWpGaD
Labetalol—ADRB2—G alpha (s) signalling events—PTHLH—osteoporosis	0.000268	0.00995	CbGpPWpGaD
Labetalol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.000259	0.00961	CbGpPWpGaD
Labetalol—ADRB3—Calcium Regulation in the Cardiac Cell—ADCY5—osteoporosis	0.000249	0.00927	CbGpPWpGaD
Labetalol—ADRB1—G alpha (s) signalling events—CALCA—osteoporosis	0.000241	0.00896	CbGpPWpGaD
Labetalol—ADRB2—G alpha (s) signalling events—CALCA—osteoporosis	0.000236	0.00876	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—CALCR—osteoporosis	0.000228	0.00849	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—PTH1R—osteoporosis	0.000228	0.00849	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—CALCR—osteoporosis	0.000223	0.0083	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—PTH1R—osteoporosis	0.000223	0.0083	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—PTH1R—osteoporosis	0.000217	0.00808	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—CALCR—osteoporosis	0.000217	0.00808	CbGpPWpGaD
Labetalol—ADRB3—G alpha (s) signalling events—POMC—osteoporosis	0.000213	0.0079	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—PTH—osteoporosis	0.000202	0.00751	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—PTH1R—osteoporosis	0.000197	0.00734	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—CALCR—osteoporosis	0.000197	0.00734	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—CNR2—osteoporosis	0.000197	0.00732	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—WNT1—osteoporosis	0.000185	0.00688	CbGpPWpGaD
Labetalol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000184	0.00683	CbGpPWpGaD
Labetalol—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000181	0.00674	CbGpPWpGaD
Labetalol—ADRB1—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.000179	0.00666	CbGpPWpGaD
Labetalol—ADRB2—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.000175	0.00651	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—MGLL—osteoporosis	0.000173	0.00642	CbGpPWpGaD
Labetalol—ADRB1—G alpha (s) signalling events—ADCY5—osteoporosis	0.000171	0.00637	CbGpPWpGaD
Labetalol—ADRB2—G alpha (s) signalling events—ADCY5—osteoporosis	0.000168	0.00623	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—PTHLH—osteoporosis	0.000168	0.00622	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—MGLL—osteoporosis	0.000157	0.00583	CbGpPWpGaD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.000154	0.0057	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—CYP27A1—osteoporosis	0.000151	0.0056	CbGpPWpGaD
Labetalol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.00015	0.00558	CbGpPWpGaD
Labetalol—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000149	0.00553	CbGpPWpGaD
Labetalol—CYP2D6—Metapathway biotransformation—CYP27A1—osteoporosis	0.000149	0.00552	CbGpPWpGaD
Labetalol—ADRB1—Calcium Regulation in the Cardiac Cell—ADCY5—osteoporosis	0.000148	0.0055	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—CALCA—osteoporosis	0.000147	0.00548	CbGpPWpGaD
Labetalol—ADRB2—Calcium Regulation in the Cardiac Cell—ADCY5—osteoporosis	0.000145	0.00538	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—CALCR—osteoporosis	0.000129	0.0048	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—PTH1R—osteoporosis	0.000129	0.0048	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—SOST—osteoporosis	0.000129	0.00479	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—CALCR—osteoporosis	0.000126	0.00469	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—PTH1R—osteoporosis	0.000126	0.00469	CbGpPWpGaD
Labetalol—ADRB1—G alpha (s) signalling events—POMC—osteoporosis	0.000126	0.00469	CbGpPWpGaD
Labetalol—ADRB2—G alpha (s) signalling events—POMC—osteoporosis	0.000123	0.00458	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—PTH—osteoporosis	0.00012	0.00446	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—PTH—osteoporosis	0.000117	0.00436	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—CALCR—osteoporosis	0.000117	0.00435	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PTH1R—osteoporosis	0.000117	0.00435	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—CNR2—osteoporosis	0.000117	0.00434	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CALCR—osteoporosis	0.000117	0.00433	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PTH1R—osteoporosis	0.000117	0.00433	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—CALCR—osteoporosis	0.000115	0.00426	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PTH1R—osteoporosis	0.000115	0.00426	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—CNR2—osteoporosis	0.000114	0.00425	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—PTH—osteoporosis	0.000114	0.00424	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—CNR2—osteoporosis	0.000111	0.00414	CbGpPWpGaD
Labetalol—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.00011	0.0041	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—WNT1—osteoporosis	0.00011	0.00408	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—WNT1—osteoporosis	0.000108	0.004	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—PTH—osteoporosis	0.000104	0.00385	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—MGLL—osteoporosis	0.000103	0.00381	CbGpPWpGaD
Labetalol—ADRB3—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000101	0.00376	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—CNR2—osteoporosis	0.000101	0.00376	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—MGLL—osteoporosis	0.0001	0.00373	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—PTHLH—osteoporosis	9.94e-05	0.00369	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—PTHLH—osteoporosis	9.73e-05	0.00361	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—WNT1—osteoporosis	9.51e-05	0.00353	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—PTHLH—osteoporosis	9.47e-05	0.00352	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—MGLL—osteoporosis	9.31e-05	0.00346	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MGLL—osteoporosis	9.27e-05	0.00344	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—MGLL—osteoporosis	9.11e-05	0.00338	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—LRP5—osteoporosis	9.05e-05	0.00336	CbGpPWpGaD
Labetalol—CYP2D6—Phase 1 - Functionalization of compounds—POMC—osteoporosis	8.95e-05	0.00333	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—CALCA—osteoporosis	8.75e-05	0.00325	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—LRP6—osteoporosis	8.65e-05	0.00321	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—PTHLH—osteoporosis	8.6e-05	0.00319	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—CALCA—osteoporosis	8.56e-05	0.00318	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—CALCA—osteoporosis	8.33e-05	0.0031	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—CYP19A1—osteoporosis	7.91e-05	0.00294	CbGpPWpGaD
Labetalol—CYP2D6—Metapathway biotransformation—CYP19A1—osteoporosis	7.81e-05	0.0029	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—POMC—osteoporosis	7.72e-05	0.00287	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—SOST—osteoporosis	7.66e-05	0.00284	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—CALCA—osteoporosis	7.57e-05	0.00281	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—SOST—osteoporosis	7.49e-05	0.00278	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—TLN1—osteoporosis	7.31e-05	0.00271	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PTH1R—osteoporosis	6.92e-05	0.00257	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CALCR—osteoporosis	6.92e-05	0.00257	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—PTH—osteoporosis	6.78e-05	0.00252	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PTH1R—osteoporosis	6.77e-05	0.00252	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CALCR—osteoporosis	6.77e-05	0.00252	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—PTH—osteoporosis	6.63e-05	0.00246	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—CNR2—osteoporosis	6.61e-05	0.00245	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—CNR2—osteoporosis	6.46e-05	0.0024	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—P4HB—osteoporosis	6.3e-05	0.00234	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PTH—osteoporosis	6.16e-05	0.00229	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PTH—osteoporosis	6.13e-05	0.00228	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PTH—osteoporosis	6.02e-05	0.00224	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—RAP1A—osteoporosis	6.02e-05	0.00224	CbGpPWpGaD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	6.01e-05	0.00223	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—CNR2—osteoporosis	6e-05	0.00223	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CNR2—osteoporosis	5.97e-05	0.00222	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—ADCY5—osteoporosis	5.93e-05	0.0022	CbGpPWpGaD
Labetalol—ADRB2—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	5.88e-05	0.00219	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—NFATC1—osteoporosis	5.88e-05	0.00218	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—CNR2—osteoporosis	5.87e-05	0.00218	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—DKK1—osteoporosis	5.83e-05	0.00217	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—WNT1—osteoporosis	5.64e-05	0.0021	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—PTHLH—osteoporosis	5.62e-05	0.00209	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—WNT1—osteoporosis	5.62e-05	0.00209	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—WNT1—osteoporosis	5.52e-05	0.00205	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MGLL—osteoporosis	5.5e-05	0.00204	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—PTHLH—osteoporosis	5.5e-05	0.00204	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—FGA—osteoporosis	5.46e-05	0.00203	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—ADCY5—osteoporosis	5.38e-05	0.002	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MGLL—osteoporosis	5.38e-05	0.002	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—LRP5—osteoporosis	5.37e-05	0.00199	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—LRP5—osteoporosis	5.25e-05	0.00195	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—LRP6—osteoporosis	5.14e-05	0.00191	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PTHLH—osteoporosis	5.1e-05	0.0019	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PTHLH—osteoporosis	5.08e-05	0.00189	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—BMP2—osteoporosis	5.08e-05	0.00189	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—LRP6—osteoporosis	5.02e-05	0.00187	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PTHLH—osteoporosis	4.99e-05	0.00185	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—FGB—osteoporosis	4.97e-05	0.00185	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—CALCA—osteoporosis	4.95e-05	0.00184	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—CALCA—osteoporosis	4.84e-05	0.0018	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PSMA5—osteoporosis	4.8e-05	0.00178	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PSMA2—osteoporosis	4.8e-05	0.00178	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—POMC—osteoporosis	4.76e-05	0.00177	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—POMC—osteoporosis	4.58e-05	0.0017	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—CALCA—osteoporosis	4.49e-05	0.00167	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PKM—osteoporosis	4.49e-05	0.00167	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—FDPS—osteoporosis	4.49e-05	0.00167	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—POMC—osteoporosis	4.48e-05	0.00166	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CALCA—osteoporosis	4.47e-05	0.00166	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—CALCA—osteoporosis	4.39e-05	0.00163	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—POMC—osteoporosis	4.36e-05	0.00162	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TLN1—osteoporosis	4.34e-05	0.00161	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PGLS—osteoporosis	4.25e-05	0.00158	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GPD2—osteoporosis	4.25e-05	0.00158	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TLN1—osteoporosis	4.24e-05	0.00158	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—KL—osteoporosis	4.06e-05	0.00151	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—POMC—osteoporosis	3.96e-05	0.00147	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PNP—osteoporosis	3.89e-05	0.00144	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ATIC—osteoporosis	3.89e-05	0.00144	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—IL6R—osteoporosis	3.86e-05	0.00143	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—P4HB—osteoporosis	3.74e-05	0.00139	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—P4HB—osteoporosis	3.66e-05	0.00136	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PTH—osteoporosis	3.64e-05	0.00135	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—RAP1A—osteoporosis	3.57e-05	0.00133	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PTH—osteoporosis	3.56e-05	0.00132	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CNR2—osteoporosis	3.54e-05	0.00132	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—ADCY5—osteoporosis	3.52e-05	0.00131	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—RAP1A—osteoporosis	3.5e-05	0.0013	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NFATC1—osteoporosis	3.49e-05	0.0013	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CNR2—osteoporosis	3.47e-05	0.00129	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—DKK1—osteoporosis	3.46e-05	0.00129	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—ADCY5—osteoporosis	3.44e-05	0.00128	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NFATC1—osteoporosis	3.41e-05	0.00127	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—DKK1—osteoporosis	3.38e-05	0.00126	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—WNT1—osteoporosis	3.33e-05	0.00124	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CA2—osteoporosis	3.31e-05	0.00123	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—OXCT1—osteoporosis	3.31e-05	0.00123	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—WNT1—osteoporosis	3.26e-05	0.00121	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FGA—osteoporosis	3.24e-05	0.0012	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—MGLL—osteoporosis	3.22e-05	0.0012	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—ADCY5—osteoporosis	3.2e-05	0.00119	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—ADCY5—osteoporosis	3.18e-05	0.00118	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FGA—osteoporosis	3.17e-05	0.00118	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—ADCY5—osteoporosis	3.13e-05	0.00116	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—SPP1—osteoporosis	3.08e-05	0.00114	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—BMP2—osteoporosis	3.01e-05	0.00112	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PTHLH—osteoporosis	3.01e-05	0.00112	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FGB—osteoporosis	2.95e-05	0.0011	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PTHLH—osteoporosis	2.95e-05	0.0011	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—BMP2—osteoporosis	2.95e-05	0.0011	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FGB—osteoporosis	2.89e-05	0.00107	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PSMA2—osteoporosis	2.85e-05	0.00106	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PSMA5—osteoporosis	2.85e-05	0.00106	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PSMA5—osteoporosis	2.79e-05	0.00103	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PSMA2—osteoporosis	2.79e-05	0.00103	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IRS2—osteoporosis	2.78e-05	0.00103	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—IDH2—osteoporosis	2.74e-05	0.00102	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—LEP—osteoporosis	2.72e-05	0.00101	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CALCA—osteoporosis	2.65e-05	0.000986	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—ESR1—osteoporosis	2.6e-05	0.000966	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CALCA—osteoporosis	2.6e-05	0.000964	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—POMC—osteoporosis	2.59e-05	0.000961	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP27A1—osteoporosis	2.58e-05	0.000957	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—POMC—osteoporosis	2.53e-05	0.000941	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ACP5—osteoporosis	2.51e-05	0.000931	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IRS1—osteoporosis	2.43e-05	0.000902	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—KL—osteoporosis	2.41e-05	0.000895	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—KL—osteoporosis	2.36e-05	0.000876	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—POMC—osteoporosis	2.35e-05	0.000873	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—POMC—osteoporosis	2.34e-05	0.000869	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—TPI1—osteoporosis	2.33e-05	0.000866	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—POMC—osteoporosis	2.3e-05	0.000854	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—IL6R—osteoporosis	2.29e-05	0.000852	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IL6R—osteoporosis	2.28e-05	0.000848	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IGF1—osteoporosis	2.25e-05	0.000836	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—IL6R—osteoporosis	2.24e-05	0.000833	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—P4HB—osteoporosis	2.19e-05	0.000814	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GAPDH—osteoporosis	2.15e-05	0.000799	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—RAP1A—osteoporosis	2.09e-05	0.000778	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ADCY5—osteoporosis	1.89e-05	0.000701	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ADCY5—osteoporosis	1.85e-05	0.000686	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—SPP1—osteoporosis	1.83e-05	0.000678	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—SPP1—osteoporosis	1.79e-05	0.000664	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—IL6—osteoporosis	1.72e-05	0.000639	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ENO1—osteoporosis	1.69e-05	0.000629	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PSMA2—osteoporosis	1.67e-05	0.00062	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PSMA5—osteoporosis	1.67e-05	0.00062	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IRS2—osteoporosis	1.65e-05	0.000614	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—LEP—osteoporosis	1.62e-05	0.0006	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IRS2—osteoporosis	1.62e-05	0.0006	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—LEP—osteoporosis	1.58e-05	0.000587	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ESR1—osteoporosis	1.54e-05	0.000573	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ESR1—osteoporosis	1.51e-05	0.000561	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IRS1—osteoporosis	1.44e-05	0.000536	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IRS1—osteoporosis	1.41e-05	0.000524	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—POMC—osteoporosis	1.39e-05	0.000516	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—POMC—osteoporosis	1.36e-05	0.000505	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IL6R—osteoporosis	1.35e-05	0.000503	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP19A1—osteoporosis	1.35e-05	0.000503	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MYC—osteoporosis	1.35e-05	0.000502	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—TGFB1—osteoporosis	1.35e-05	0.000501	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IGF1—osteoporosis	1.34e-05	0.000496	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IL6R—osteoporosis	1.32e-05	0.000492	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IGF1—osteoporosis	1.31e-05	0.000485	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ADCY5—osteoporosis	1.11e-05	0.000411	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GPX1—osteoporosis	1.1e-05	0.000409	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—IL6—osteoporosis	1.02e-05	0.000379	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—MTHFR—osteoporosis	1.02e-05	0.000378	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IL6—osteoporosis	1.02e-05	0.000378	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—IL6—osteoporosis	9.99e-06	0.000371	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—POMC—osteoporosis	8.13e-06	0.000302	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MYC—osteoporosis	8.03e-06	0.000298	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TGFB1—osteoporosis	8.01e-06	0.000297	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MYC—osteoporosis	7.85e-06	0.000292	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TGFB1—osteoporosis	7.83e-06	0.000291	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IL6—osteoporosis	6.03e-06	0.000224	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IL6—osteoporosis	5.9e-06	0.000219	CbGpPWpGaD
